Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852880 | 0.85 | OTUD7B (0.43) | ITGB3ITGA2BOTUD7BCALCRL | |
| SCHEMBL19852881 | 0.82 | OTUD7B (0.43) | OTUD7BCALCRL | |
| SCHEMBL29890275 | 0.80 | OTUD7B (0.46) | OTUD7BCALCRL | |
| SCHEMBL29360897 | 0.79 | OTUD7B (0.43) | OTUD7BCALCRL | |
| SCHEMBL24338486 | 0.79 | OTUD7B (0.36) | OTUD7BCALCRL | |
| SCHEMBL24620331 | 0.78 | OTUD7B (0.35) | OTUD7BCALCRL | |
| SCHEMBL24620526 | 0.77 | OTUD7B (0.35) | OTUD7BCALCRL | |
| SCHEMBL23934060 | 0.76 | ITGB3 (0.34) | ITGB3ITGA2BATM | |
| SCHEMBL745671 | 0.75 | OTUD7B (0.40) | OTUD7BCALCRL | |
| SCHEMBL4072997 | 0.75 | OTUD7B (0.47) | OTUD7BCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2018026779-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | ITGB3 3250/4885ITGA2B 2064/4885ATM 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.